Canada markets open in 2 hours 6 minutes
  • S&P/TSX

    20,985.37
    +57.27 (+0.27%)
     
  • S&P 500

    4,486.46
    +15.09 (+0.34%)
     
  • DOW

    35,258.61
    -36.15 (-0.10%)
     
  • CAD/USD

    0.8111
    +0.0031 (+0.38%)
     
  • CRUDE OIL

    83.52
    +1.08 (+1.31%)
     
  • BTC-CAD

    76,663.68
    +760.64 (+1.00%)
     
  • CMC Crypto 200

    1,450.89
    -0.75 (-0.05%)
     
  • GOLD FUTURES

    1,777.30
    +11.60 (+0.66%)
     
  • RUSSELL 2000

    2,267.84
    +2.19 (+0.10%)
     
  • 10-Yr Bond

    1.5840
    0.0000 (0.00%)
     
  • NASDAQ futures

    15,354.00
    +63.50 (+0.42%)
     
  • VOLATILITY

    16.04
    -0.26 (-1.60%)
     
  • FTSE

    7,208.03
    +4.20 (+0.06%)
     
  • NIKKEI 225

    29,215.52
    +190.06 (+0.65%)
     
  • CAD/EUR

    0.6952
    -0.0003 (-0.04%)
     

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BRISBANE, Calif., August 31, 2021--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in fireside chats at the following investor conferences:

  • 2021 Virtual Wells Fargo Healthcare Conference
    Date: Friday, September 10th at 3:20 p.m. Eastern Time

  • H.C. Wainwright & Co. 23rd Annual Global Investment Conference
    Date: Monday, September 13th at 7:00 a.m. Eastern Time

  • Morgan Stanley 19th Annual Global Healthcare Conference
    Date: Wednesday, September 15th at 10:15 a.m. Eastern Time

For presentations that are webcast live, an access link will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentations will also be available on the Sangamo Therapeutics website after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. For more information about Sangamo, visit www.sangamo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005047/en/

Contacts

Investor Relations & Media Inquiries
Aron Feingold
628.252.7494
afeingold@sangamo.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting